Adult survivors of Hodgkin lymphoma face nearly twice the all-cause mortality rate of the general United States population, with cardiovascular disease and noncancer conditions driving the largest absolute number of excess deaths, according to a population-based retrospective cohort study published in JAMA Network Open by Valcarcel B et al.
Hodgkin Lymphoma Long-Term Mortality Rates
Despite these high survival rates, long-term health risks persist long after patients finish initial treatment.
The retrospective cohort study analyzed 20,057 adults aged 20 or older who received a first primary Hodgkin lymphoma diagnosis between 2000 and 2017. Researchers pulled data from 16 population-based registries within the Surveillance, Epidemiology, and End Results (SEER) program. To qualify for the analysis, patients must have undergone chemotherapy with or without radiotherapy and survived for at least 5 years following their diagnosis.
During the follow-up period stretching through December 2023, researchers recorded 2,899 deaths among the cohort. By comparison, researchers expected only 1,480.8 deaths based on mortality rates in the general US population, adjusted for age, sex, race and ethnicity, and calendar period. This discrepancy resulted in a standardized mortality ratio of 1.96, meaning survivors experienced nearly double the mortality risk of the general public.
Did you know? The median age of the study cohort at diagnosis was 36 years old, and male patients accounted for 53.7% of the total analyzed population. Nodular sclerosis was the most common presentation, reported in 63.4% of patients.
Causes of Excess Mortality Among Survivors
While malignant conditions remained the primary contributor to relative mortality risk across all major causes of death, they did not account for the highest volume of additional fatalities. According to the study findings, the largest absolute number of excess deaths stemmed from cardiovascular issues and other noncancer health problems.
The excess absolute risk calculated by the research team reached 81.9 additional deaths per 10,000 patient-years. Specific demographic groups experienced even higher relative risks. Standardized mortality ratios exceeding 2.50 appeared among Hispanic survivors, non-Hispanic American Indian or Alaska Native survivors, non-Hispanic Asian or Pacific Islander survivors, and individuals diagnosed between the ages of 20 and 39.
Furthermore, the highest excess absolute risks concentrated among survivors aged 60 to 89 years, non-Hispanic American Indian or Alaska Native participants, and patients diagnosed with mixed-cellularity disease. At a median follow-up of 173 months from diagnosis, the 10-year cumulative mortality rate hit 8.0%. Of this total, 2.5% stemmed from non-cancer-related factors, 2.1% from alternate neoplasms, 1.6% from cardiovascular issues, and another 1.6% was attributed directly to Hodgkin lymphoma. By 15 years post-diagnosis, the cumulative mortality rate rose to 15.0%.
Implications for Modern Survivorship Care
The study provides crucial population-based estimates specifically focused on adults treated during the contemporary era of risk-adapted therapy. Previous mortality literature often relied heavily on childhood cancer cohorts, shorter follow-up intervals, or older treatment generations that preceded modern clinical strategies.
These findings suggest that oncology care teams must broaden long-term survivorship protocols. Because cardiovascular and noncancer conditions drive the greatest absolute excess in deaths, follow-up care requires rigorous monitoring of heart health and secondary health screenings alongside routine cancer surveillance. Funding for this investigation was provided by the Robert A. Winn Clinical Investigator Leadership Award, the Birdies Fore Logan Foundation, and the American Society of Hematology Amos Medical Faculty Development Program.
As newer immunotherapies like brentuximab vedotin and nivolumab become standard, ongoing population-based surveillance will remain essential to track how modern drug classes influence long-term survival patterns and late-effect risks.
Frequently Asked Questions
What is the long-term survival rate for Hodgkin lymphoma?
Why do Hodgkin lymphoma survivors face higher mortality rates?
Long-term survivors face nearly twice the all-cause mortality rate of the general population. While recurrent or new malignancies contribute significantly to relative risk, cardiovascular diseases and noncancer health issues account for the largest absolute number of excess deaths.
Who was included in the SEER program mortality analysis?
The study evaluated 20,057 adult survivors aged 20 or older diagnosed with first primary Hodgkin lymphoma between 2000 and 2017 who survived for at least 5 years after receiving chemotherapy with or without radiotherapy.
Which groups experienced the highest relative mortality risk?
Standardized mortality ratios higher than 2.50 occurred among Hispanic survivors, non-Hispanic American Indian or Alaska Native survivors, non-Hispanic Asian or Pacific Islander survivors, and adults diagnosed between 20 and 39 years of age.
What are your thoughts on how survivorship care should adapt to these findings? Share your perspective in the comments below, or subscribe to our newsletter for the latest oncology research updates.
Keep reading
- NIN Study Links Lead Exposure to Nerve Cell Damage
- Moderna and Merck Achieve Breakthrough with Personalized Melanoma Treatment
- Connected Cars: New Report Warns of Major Privacy and Security Risks (archynewsy.com)
- Bangladesh China Human Trafficking: Inside the Ordeal of a Bangladeshi Woman Trafficked to China – A Journey of Survival and Resilience” Keyword Density: – Bangladesh: 2.3% – China: 2.1% – Human Trafficking: 2.4% – Trafficked: 1.9% – Woman: 1.7% – Ordeal: 1.3% – Survival: 1.1% – Resilience: 0.9% Meta Description: “Read the harrowing true story of a Bangladeshi woman trafficked to China, highlighting the dark side of human trafficking and the struggles of survivors.” Header Tags: – H1: Bangladesh China Human Trafficking: Inside the Ordeal of a Bangladeshi Woman Trafficked to China – H2: The Journey Begins: How a Bangladeshi Woman Was Lured into China – H2: Life in Captivity: The Harsh Reality of Human Trafficking in China – H2: Finding Hope: The Struggle for Survival and Resilience (archyworldys.com)